60 Degrees Pharmaceuticals (NASDAQ:SXTP) Price Target Raised to $24.00 at HC Wainwright

60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its target price boosted by HC Wainwright from $6.00 to $24.00 in a research report sent to investors on Tuesday morning, MarketBeat Ratings reports. The brokerage currently has a buy rating on the stock.

A number of other analysts have also issued reports on the stock. Zacks Research upgraded shares of 60 Degrees Pharmaceuticals to a “hold” rating in a research note on Tuesday, November 18th. Ascendiant Capital Markets decreased their target price on 60 Degrees Pharmaceuticals from $12.00 to $11.20 and set a “buy” rating for the company in a research note on Friday, November 28th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $17.60.

60 Degrees Pharmaceuticals Price Performance

NASDAQ:SXTP opened at $4.82 on Tuesday. The firm has a market capitalization of $5.11 million, a PE ratio of -1.39 and a beta of 2.98. 60 Degrees Pharmaceuticals has a 12 month low of $1.36 and a 12 month high of $24.00. The business’s 50-day moving average is $3.20 and its two-hundred day moving average is $4.74.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($2.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.84) by $2.20. The firm had revenue of ($0.01) million during the quarter, compared to analyst estimates of $0.38 million. Equities analysts anticipate that 60 Degrees Pharmaceuticals will post -5.09 EPS for the current year.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.